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CRISPR/Cas9-mediated gene 
modification and gene knock out 
in the human-infective parasite 
Trichomonas vaginalis
Brian D. Janssen1, Yi-Pei Chen1,2, Brenda M. Molgora1,2, Shuqi E. Wang  3, Augusto Simoes-
Barbosa3 & Patricia J. Johnson1,2
The sexually-transmitted parasite Trichomonas vaginalis infects ~1/4 billion people worldwide. Despite 
its prevalence and myriad adverse outcomes of infection, the mechanisms underlying T. vaginalis 
pathogenesis are poorly understood. Genetic manipulation of this single-celled eukaryote has been 
hindered by challenges presented by its complex, repetitive genome and inefficient methods for 
introducing DNA (i.e. transfection) into the parasite. Here, we have developed methods to increase 
transfection efficiency using nucleofection, with the goal of efficiently introducing multiple DNA 
elements into a single T. vaginalis cell. We then created DNA constructs required to express several 
components essential to drive CRISPR/Cas9-mediated DNA modification: guide RNA (gRNA), the 
Cas9 endonuclease, short oligonucleotides and large, linearized DNA templates. Using these technical 
advances, we have established CRISPR/Cas9-mediated repair of mutations in genes contained on 
circular DNA plasmids harbored by the parasite. We also engineered CRISPR/Cas9 directed homologous 
recombination to delete (i.e. knock out) two non-essential genes within the T. vaginalis genome. 
This first report of the use of the CRISPR/Cas9 system in T. vaginalis greatly expands the ability to 
manipulate the genome of this pathogen and sets the stage for testing of the role of specific genes in 
many biological processes.
Trichomonas vaginalis is an obligate extracellular, unicellular flagellated protozoan parasite and the causative 
agent of trichomoniasis, an infection that afflicts ~¼ billion people worldwide1. Infection can be asymptomatic or 
result in a variety of negative outcomes in women and men including vaginitis, cervicitis, pelvic inflammatory dis-
ease, prostatitis and urethritis2,3. Alarmingly, public health studies have reported an increased incidence of drug 
resistance to the drug used to treat infections, metronidazole4–7. Despite being a very common sexually transmit-
ted infection, the basic mechanisms underlying pathogenesis and drug resistance are poorly understood. This is 
in part due to the slow adoption of molecular tools to study the genes and proteins involved in these processes8,9. 
The development and application of cutting-edge gene technologies to manipulate this medically-important par-
asite are needed to further advance our knowledge of disease mechanisms.
Studies aimed to test the function of T. vaginalis genes have been limited by inefficient methods of genomic 
manipulation. Most reports have relied on isolates naturally lacking expression of particular genes10–22 or those 
directed by lab-acquired mutations23–27 that result in changes in gene expression. Only two studies have reported 
gene knockout of non-essential proteins by integrating a drug resistance selection cassette in the gene locus relying 
purely on homologous recombination28,29. A few reports have also utilized knockdown-based strategies utilizing 
antisense RNA expression30,31 and modified oligonucleotides32,33. Knockdown techniques do not result in elimination 
of gene expression, which is often required to effectively test gene function, limiting the usefulness of this technology.
Recent advances in in vivo gene modification techniques have increased the ability to test gene function in 
both model and non-model organisms. The CRISPR (clustered regularly interspaced short palindromic repeats) 
system has recently revolutionized the ability to specifically target genes for modification in many organisms34–37. 
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The CRISPR system is composed of two components, the Cas9 double stranded DNA nuclease of Streptococcus 
pyogenes and a user-customized version of its cofactor (guide RNA) to selectively target genes and induce dou-
ble stranded DNA breaks. The double stranded breaks are repaired by non-homologous end joining (NHEJ), 
microhomology-mediated end joining (MMEJ) or homology-directed repair (HDR) pathways36,38. In many 
organisms, Cas9-gRNA expression induces repair of the double stranded break by the NHEJ and MMEJ path-
ways, which can result in insertion (NHEJ) or deletions (NHEJ and MMEJ) of nucleotides that may cause gene 
disruption and loss-of-function mutations. A more directed approach utilizes Cas9-gRNA in combination with a 
provided DNA template containing homology to the repair site to direct specific user-defined gene modifications. 
This approach requires a small region of donor DNA homology around the site of modification. More recently, 
CRISPR-based techniques have been applied to modify genes in a variety of parasitic protozoa39–50 and have been 
proposed for multicellular parasites51.
Here we report the first application of CRISPR/Cas9 to alter genes in T. vaginalis. We demonstrate Cas9-gRNA 
directed modification of a nanoluciferase reporter gene using homology directed repair. Cas9-gRNA mediated 
knockout of two endogenous T. vaginalis genes by replacement with a drug resistance gene cassette were also 
achieved. This report lays the foundation for further development and utilization of this CRISPR/Cas9 to rigor-
ously test gene function in this understudied parasite.
Results
Expression of Cas9 and gRNA in Trichomonas vaginalis. To date only two genes are reported28,29 
to have been deleted (i.e. knocked out) from the haploid genome52 of the human parasite T. vaginalis. In order 
to improve the ability to modify T. vaginalis genes, we have developed the use of the CRISPR/Cas9 system as a 
means to directly modify genes in this parasite. One technical problem encountered when developing CRISPR/
Cas9 in several systems is the toxicity associated with Cas9 expression in vivo43. In initial experiments in which 
cas9 was constitutively expressed using our standard T. vaginalis expression vector (pMasterNEO)53 and selection 
with G418, we were unable to select viable parasites, consistent with possible Cas9 toxicity. To address whether 
Cas9 was toxic in T. vaginalis cells selected for stable expression, we cloned the cas9 gene as a fusion protein with 
an N-terminal FKBP destabilization domain (FKBP-DD). The presence of this domain on a protein results in the 
degradation of the protein in the absence of the stabilizing ligand, Shield-154,55. We also added both a hemagglu-
tinin (HA) tag and two SV40 C-terminal nuclear localization motifs56 at the 3′ end of Cas9, to allow detection 
of the protein by immunoblot and to direct it into the nucleus, respectively (pMN:fkbp-cas9; Fig. 1A). Using 
this construct, we were able to transfect and G418 select for parasites with the pMN::kfbp-Cas9 plasmid in the 
presence or absence of the stabilization ligand Shield-1. Regulating the expression of Cas9 using the FKBP-DD 
and Shield-1 greatly reduced, but did not eliminate, basal expression of the FKBP-Cas9 protein in the absence 
of Shield-1 (Fig. 1B). We found that a low concentration of Shield-1 (0.1 μM) resulted in ~4-fold increased sta-
bilization of the FKBP-Cas9 protein compared to cultures lacking Shield-1. A greater than 6.5-fold increase was 
observed using 1 μM Shield-1 (Fig. 1B). Moreover, we noticed no growth difference in parasites containing the 
pMN::fkbp-cas9 plasmid compared to parasites transfected with an empty vector (pMN::EV) when grown in the 
absence of Shield-1 (data not shown). Upon addition of Shield-1 parasite numbers were reduced in the pMN::fk-
bp-cas9 transfectants compared to the pMN::EV parasites which did not exhibit growth rate reduction (data not 
shown), confirming the initial suspicion that Cas9 might exhibit toxicity in T. vaginalis.
We then made a construct that would allow the expression of gRNA(s) using the pMasterNEO plasmid 
backbone (Fig. 1C; see Methods for details). The gRNA construct (pMN::gRNA) contains the 360 bp sequence 
upstream of the U6 transcription start site (TSS), and is flanked at the 3′ end by the original 37 bp downstream 
of the U6 transcription unit to ensure proper transcription termination57. Between these 5′ and 3′ regulatory ele-
ments, we inserted the first 20 nt sequence of the U6 snRNA transcript (5′- AGCTGAGGATATGGCCTAGT)57 
followed by the conserved 76 bp scaffold sequence necessary for Cas9 targeting specificity and gRNA interaction, 
respectively (Fig. 1C). To evaluate whether transcription of this small RNA (a gRNA mimic) would be driven 
by the putative T. vaginalis U6 promoter, we performed RT-PCR on total RNA extracts from cells transfected 
with this construct (pMN::gRNA). Transcription was only detected from cells transfected with this construct 
(Fig. 1D) and was absent in negative control samples, transfected with an empty vector (pMN::EV). Next, sequen-
tial mutagenesis was done to replace the first 20 nt of T. vaginalis U6 snRNA, except for the first adenosine. None 
of the nt substitutions had an effect on transcription by end-point RT-PCR (data not shown). While the first 
transcribed nucleotide in the U6 transcript of metazoans and plants is typically a guanosine, T. vaginalis uses an 
adenosine57. Since the first transcribed nucleotide is necessary for U6 transcription in other systems58, but dispen-
sable for the DNA target specificity of the Cas9 gRNA59, we did not alter the +1 adenosine in our gRNA construct. 
The ability of the 360 nts upstream of the T. vaginalis U6 gene to drive transcription of an internally altered U6 
gene indicates that the T. vaginalis U6 gene uses an upstream promoter as is found in metazoans and plants, and 
does not rely on internal promoter sequences as described for some unicellular eukaryotes (e.g. yeast and trypa-
nosomes)60–62. These data also demonstrate that the T. vaginalis U6 promoter can be used to drive transcription 
of a sequence-customizable gRNA. In metazoan and plants, the core promoter of the U6 snRNA gene sits within 
the first ~70 bp upstream of the TSS60. In T. vaginalis, the core promoter of the U6 snRNA gene is unknown 
however we observed by end-point RT-PCR that there was no effect on transcription when the upstream region 
was reduced from 360 bp to 131 bp (data not shown). All additional gRNA plasmids produced contain the 360 nt 
sequence 5′ of the U6 gene (Fig. 1C) preserving the +1 adenosine followed immediately by a 19 nt seed region 
that is customized to target the gene of interest.
Increasing transfection efficiency of Trichomonas vaginalis. Previous reports on transfection of 
T. vaginalis have used electroporation to deliver plasmids, linearized DNA or small oligonucleotides into the 
cell53. Although sufficient to introduce DNA, transfection efficiency using this method is low. With the need 
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to introduce multiple DNAs into the same cell to achieve CRISPR/Cas9 editing, we sought to improve the 
transfection efficiency using the Amaxa nucleofection system39,63–65. We first compared electroporation versus 
nucleofection using the nanoluciferase reporter system47,63. Nanoluciferase (also termed NanoLuc) is a newly 
developed luciferase gene from a deep sea shrimp that produces stronger bioluminescence than the firefly lucif-
erase (Promega). After normalization of parasite numbers, we subjected cells to either electroporation using our 
previously described protocol53 or nucleofection to introduce the wild-type nanoluciferase gene with a duplicate 
hemagglutinin (HA) tag at the 3′end (pMN::nluc) (Fig. 2A). To optimize nucleofection, multiple programs and 
buffers were tested. Two of the programs tested (D-023 and X-001) and buffer (Parasite-2) resulted in detection 
of nanoluciferase signal compared to controls, however the signal was less than that obtained using standard 
electroporation (Supplemental Figure 1 and Fig. 2B). We found that one program (U-033) yielded better nano-
luciferase signal, although parasite survival was low (<25% of untransfected controls at +24 hours post transfec-
tion, comparable to electroporation). Increased nanoluciferase signal was observed for two nucleofection buffers 
tested, T-cell and Parasite-1. As predicted, cells transfected with the pMN::nluc(stop) plasmid containing a pre-
mature stop codon that eliminates nanoluciferase protein production (Fig. 2A and B) produced only background 
signals. In comparison to the signal intensity achieved using nucleofection we found that nanoluciferase sig-
nals measured from parasites electroporated with pMN::nluc barely increased over background signal (Fig. 2B). 
This is consistent with the low frequency of transfection of parasites by electroporation, 3% at best for surviving 
Figure 1. Setup of pMN::fkbp-cas9 and pMN::gRNA constructs. (A) Cartoon representation (not to scale) of 
pMN::fkbp-cas9 plasmid. The T. vaginalis gene α-SCS 5′ and 3′ UTRs of the pMasterNEO plasmid (pMN)53 
drive expression of the fkbp(FKBP destabilization domain)-cas9 fusion gene. The cas9 variant used is the human 
codon optimized version with 2 SV40 nuclear localization signals at the C-terminus56. (B) Representative 
immunoblot analysis (inset) and quantification of replicate samples of pMN::fkbp-cas9 expression. Samples 
were induced for 24 hours with 0, 0.1, 0.5 or 1 μM Shield-1 ligand before protein was collected and resolved by 
SDS-PAGE. Inset, upper: anti-Cas9 immunoblot (Clontech); Inset, lower: anti-TvGAPDH antibody (Cocalico 
Biologicals). Control sample used a pMN::EV (pMasterNEO::empty vector) transfectant. Quantitative 
comparison of samples utilized normalized signal of Cas9 (upper blot) to GAPDH signal (lower blot) taken 
from within an experiment and analyzed in parallel on separate immunoblots using a Bio-Rad Gel Doc and 
ImageLab software. Bar graph represents average +/− standard deviation of two independent analyses. (C) 
Cartoon representation (not to scale) of pMN::gRNA – 360 bp of the T. vaginalis U6 5′ UTR and 37 bp of the 
3′ UTR flank the gRNA. A 20 nt seed region with the first nucleotide always an adenine residue followed by 
19 nt seed region used for specific targeting and the gRNA scaffold. (D) RT-PCR products amplifying either 
the gRNA sequence or the U6 snRNA (control). Total RNA was subjected to +/− reverse transcriptase then 
amplified by PCR using gRNA- or U6 snRNA-specific primers. Control PCRs included the pMN::EV and 
pMN::gRNA plasmids, genomic DNA and no DNA template. PCR products were imaged using a Bio-Rad Gel 
Doc and ImageLab software. Full length blots/gels are presented in Supplementary Figure S5.
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Figure 2. Parameters for transfection of Trichomonas vaginalis for detection of nanoluciferase activity. (A) 
Cartoon representation of nanoluciferase plasmids and predicted outcome for protein production. (B) A total of 
1 × 107 parasites were either nucleofected using the U-033 (“U”) or D-023 (“D”) programs (Amaxa) or mock (no 
nucleofection) with 10 μg of pMN::nluc or pMN::nluc(stop) in buffers Parasite-1 or T-cell (Lonza) or electroporated 
(975 μF, 350 V, Bio-Rad) in completed TYM media. Plasmids are pMN::nluc, denoted as “nluc” and pMN::nluc(stop), 
denoted as “nluc(stop)” where indicated. Parasites were immediately recovered in completed TYM media. After 
24 hours, a total of 1 × 106 parasites were collected and nanoluciferase activity was measured by NanoGlo assay 
(Promega). Graph represents the average relative luminescence value +/− standard deviation of two transfections 
per condition. (C) Samples transfected with the pMN::nluc or pMN::nluc(stop) constructs and the U-033 program 
from Fig. 2B were subjected to G418-selection and allowed to grow for an additional +24 hours (+48 hours total, 
post-transfection). Equivalent numbers of parasites (1 × 106) were assayed for nanoluciferase activity and the graph 
represents the average relative luminescence value +/− standard deviation of two attempts per condition.
www.nature.com/scientificreports/
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cells66. Nucleofection with the U-033 program increased nanoluciferase signal 18-fold using Parasite-1 buffer and 
30-fold using T-cell buffer, relative to signals detected using electroporation.
To determine if signal was stable and detectable at later time points, we passaged the parasites in the presence 
or absence of 100 μg/ml G418 to select for the pMN::nluc and pMN::nluc(stop) plasmids (Fig. 2C). We noted that 
G418 selection for the pMN::nluc plasmid resulted in high levels of detectable nanoluciferase activity compared 
to transient nucleofection (Figures S2 and S3). The overall nanoluciferase signal for the unselected pMN::nluc 
parasites was reduced at +48 hours post-nucleofection compared to +24 hours. Selection for parasites harboring 
the pMN::nluc plasmids using G418 resulted in a dramatic increase with greater than 20 fold higher nanolucif-
erase signal compared to those transiently nucleofected (Fig. 2C). Electroporation did not yield the same increase 
(average ~1.2-fold) over the unselected counterparts (Fig. 2C and Fig. S3). Based on these data, we selected the 
U-033 program and the T-cell buffer as the optimal conditions to use for nucleofection of this strain of T. vagi-
nalis. Together, these data demonstrate that nucleofection greatly improves transfection efficiency of T. vaginalis.
CRISPR repair of a dead-luciferase gene in Trichomonas vaginalis. To test the activity of Cas9, we 
used the highly-sensitive nanoluciferase repair assay originally described by Striepen and colleagues47. To express 
the DD- Cas9 and gRNAs together in T. vaginalis, we first constructed a plasmid containing both elements as 
well as a puromycin acetyltransferase (PAC) gene, pCas9-gRNA(nluc) (Fig. 3A). As outlined in Fig. 2A, we then 
preselected parasites containing the plasmid that expresses a dead luciferase (i.e. pMN::nluc(stop)) using G418. 
We subsequently co-nucleofected preselected parasites with the pCas9-gRNA(nluc) plasmid expressing a gRNA 
targeting the premature stop codon (Y18ochre) region of the gene and pre-annealed oligos capable of both repair-
ing the stop codon (“repaired”, ochre18Y) and introducing a mutation that eliminates the PAM (AGG- > AGC). 
Mutation of the PAM requires the correction of two sites by oligo template-directed repair, increasing the confi-
dence that repair is Cas9-gRNA directed, and not due to random point mutation that changed a stop codon back 
to a tyrosine codon. Mutation also prevents further targeting of the repair site by Cas9-gRNA(nluc). Transient 
nucleofection was used, without drug selection for expression of the gRNA or Cas9. Using this approach, we were 
able to demonstrate that CRISPR/Cas9 is capable of repairing the mutation to allow detection of nanoluciferase 
signal above background levels in T. vaginalis (Fig. 3).
The nanoluciferase repair assays were done using different lengths of oligos (50 nt and 125 nt) and we found 
that although the 50 bp annealed oligos yielded similar or better efficiency of repair, more variability was also 
observed (Fig. 3B). We also tested the use of PCR products corresponding to the 125 bp annealed oligos and the 
full length nluc gene. These also repaired pMN::nluc(stop), restoring nanoluciferase activity (Fig. 3C) however, 
the efficiency was not increased.
To further explore the ability to utilize CRISPR/Cas9 in T. vaginalis, we co-nucleofected parasites with 
pCas9-gRNA(nluc), pMN::nluc(stop) and either the 50 bp or 125 bp annealed repair oligos and selected for para-
sites containing both the pCas9-gRNA(nluc) (puromycin selection) and pMN::nluc(stop) (G418 selection) plas-
mids (Fig. 4A). Assaying for nanoluciferase signal 24 hours post-nucleofection, prior to drug selection, yielded 
a low overall signal compared to previous nucleofections (Fig. 4B). This is likely the result of requiring the same 
parasite to acquire all three DNAs to allow Cas9-directed repair. We also found that the 50 bp annealed oligo 
treatment did not work effectively, compared to previous experiments using parasites preselected to contain 
pMN::nluc(stop) target. Conversely, treatment with the 125 bp annealed oligos yielded a ~six-fold increase in 
nanoluciferase signal over background (water).
We then subjected the nucleofected parasites to selection with G418 and puromycin for either 7 or 14 days 
and tested for nanoluciferase activity. The amount of nanoluciferase signal observed was very high for parasites 
nucleofected with the 125 bp repair oligos (Fig. 4C). This signal did not increase between the 7 and 14 day meas-
urements. To confirm expression of intact nanoluciferase protein at 14 days, total protein was extracted and 
analyzed by immunoblot analysis for the presence of repaired nanoluciferase-2xHA. We observed expression of 
the protein in parasites nucleofected with all three DNAs (pCas9-gRNA(nluc), pMN::nluc(stop) and the 125 bp 
annealed repair oligos), but not in parasites where the pCas9-gRNA (nluc) was replaced with an empty vector 
(pMPAC::EV) (Fig. 4C, inset), consistent with the nanoluciferase activity assay. These data show that the repair 
of the dead luciferase was dependent on the presence of both essential components of the CRISPR/Cas9 system: 
the Cas9 and gRNA.
To confirm the repair of nanoluciferase by directly examining the DNA sequence of the luciferase gene, we 
cloned parasites from a selected population demonstrated to express the enzyme by activity and immunoblot 
assays, using limiting dilution. We then assayed 79 clones for nanoluciferase activity and observed that 91% (72 
clones) gave signal above background, while 9% (7 clones) were below a cutoff of 30,000 relative luminescence 
units. The high percentage of clones expressing nanoluciferase indicates that the majority of parasites in the cul-
ture were expressing a repaired nanoluciferase gene. To support this observation, we collected total protein from 
8 clones and performed immunoblot analysis (Fig. 4D, upper). Although varied in amount of observable signal, 
we were able to detect nanoluciferase signal in all 8 clones. We further PCR amplified and then sequenced the nluc 
gene from total gDNA extracts of 8 clones (Fig. 4D, lower). In all 8 clones, the codon 17 contained a mixed popu-
lation of guanine (GGA, glycine) and cytosine (GCA, alanine) sequence. Additionally, without exception, codon 
18 contained a mixed population of thymine (TAT, tyrosine) and adenine (TAA, ochre/stop). The presence of a 
mixed population of nluc(stop) (GGATAA or GCATAA) and nluc(repaired) (GGATAT or GCATAT) sequences 
in the examined clones is expected. Our previous study indicates that ~15–20 episomes are maintained per T. 
vaginalis cell53, hence CRISPR/Cas9-mediated repair may not reach every single plasmid copy within a cell. In 
fact, repair of a single modified nluc(stop) gene would likely be sufficient to be detectable by DNA sequencing and 
to produce enough luciferase activity for detection using the sensitive NanoGlo assay (Figure S2). Together, the 
data presented clearly demonstrate that the expression of Cas9 & gRNAs in T. vaginalis can mediate gene repair 
via the CRISPR/Cas9 pathway.
www.nature.com/scientificreports/
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Figure 3. Nanoluciferase repair assay. (A) Upper: cartoon representation of nanoluciferase repair assay. Below: 
Cas9-gRNA(nluc) editing sites of nluc(stop) with mutation to create a premature stop codon (red, underlined). 
Also represented are the wild-type (nluc) and repaired (nluc(repaired)) versions. (B) A total of 5 × 107 parasites 
pre-selected for the pMN::nluc(stop) plasmid were nucleofected in T-cell buffer using the U-033 program 
(Amaxa) with 10 μg or 100 μg of annealed repair oligos and 10 μg of pCas9-gRNA(nluc). Oligos contained the 
repair sequence and either 50 bp or 125 bp annealed repair oligos. Parasites were immediately recovered in 
completed TYM media +/− 1 μM Shield-1 and assayed for nanoluciferase activity after 24 hours. Equivalent 
numbers of parasites (1 × 106) were assayed for nanoluciferase activity and the graph represents the average 
relative luminescence value +/− standard deviation for each condition. (C) A total of 5 × 107 parasites pre-
selected for pMN::nluc(stop) were nucleofected in T-cell buffer using the U-033 program (Amaxa) with 10 μg 
pCas9-gRNA(nluc) and either 100 μg of PCR-amplified 125 bp repair sequence (equivalent to ds repair oligos) 
or the full length nluc (“Full nluc PCR”) sequence. Parasites were immediately recovered in  completed TYM 
media + 1 μM Shield-1 and assayed for nanoluciferase activity after 24 hours. Equivalent numbers of parasites 
(1 × 106) were assayed for nanoluciferase activity and the graph represents the average relative luminescence 
value +/− standard deviation for each condition.
www.nature.com/scientificreports/
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CRISPR knockout of the Ferredoxin-1 and Mif genes from the T. vaginalis genome. To test 
whether the CRISPR/Cas9 system we have established is capable of knocking out a gene in the complex T. vagina-
lis genome, we first attempted to knockout the ferredoxin-1 (Fd-1) gene previously shown to be non-essential to 
the parasite29,67. A neomycin resistance (NeoR) gene flanked by ~1000 bp of the 5′ and 3′ UTRs of Fd-1 was con-
structed (Fig. 5A). Parasites were co-nucleofected with either the pMPAC::EV or the pCas9-gRNA(Fd) plasmid that 
expresses a gRNA targeting the 5′ end of the gene and an ~2800 bp PCR product containing the NeoR genes flanked 
by Fd-1 gene 5′ and 3′ UTRs (Fig. 5A). After selection for parasites resistant to G418, parasites were screened 
for the presence of the NeoR gene in the Fd-1 locus, using PCR and primers that sit just outside the Fd-1 UTRs 
included in the ~2800 bp PCR product. Positive amplicons of expected size were observed in the pCas9-gRNA(Fd) 
nucleofected parasites, while the pMPAC::EV parasites did not grow as expected. We then obtained cloned para-
sites from a NeoR positive population using limited-dilution cloning. Two clones (2–2 G4 “ΔFd-1 clone 1” and 2-1 
D9 “ΔFd-1 clone 2”) were randomly selected and tested for the presence of the NeoR gene as well as the wild-type 
Fd-1 gene (Fig. 5B). Confirmation of the sequence of all PCR products clearly demonstrates that both clones con-
tain the NeoR gene in the Fd-1 locus and to also lack the endogenous Fd-1 gene (Fig. 5B). Immunoblot analysis 
using an antibody that detects Fd-167 also confirmed the loss of Fd-1 protein in both clones (Fig. 5C).
Figure 4. Transient transfection, selection and screening for nanoluciferase repair. (A) Cartoon representation 
of transient nanoluciferase repair activity assay followed by selection with puromycin and G418. (B) A total 
of 5 × 107 parasites were nucleofected with 10 μg of pCas9-gRNA(nluc), 10 μg pMN::nluc(stop) and 100 μg 
of either 50 bp or 125 bp annealed repair oligos or water using T-cell buffer (Lonza) and the U-033 program 
(Amaxa). Parasites were immediately recovered in completed TYM media + 1 μM Shield-1. After 24 hours 
of recovery, equivalent numbers of parasites (1 × 106) were assayed for nanoluciferase activity and the 
graph represents the average relative luminescence value +/− standard deviation from duplicate samples 
for each condition (C). After 24 hours of recovery, one transfection population of the pMPAC::EV- and 
pCas9-gRNA(nluc)-treated parasites from Fig. 4B was treated with 30 μg/ml puromycin and 50 μg/ml G418 
to select for parasites transfected with both plasmids. After 7 and 14 days (post-nucleofection), parasites 
were re-tested for nanoluciferase activity by assay of equivalent numbers of parasites (1 × 106). The graph 
represents the average relative luminescence value +/− standard deviation for each condition. Inset: Anti-HA 
epitope immunoblot analysis of control samples (pre-selected parasites) compared to protein isolated from 
puromycin/G418 selected parasites grown for two weeks. (D) Upper: anti-HA epitope immunoblot analysis 
of controls (pre-selected plasmids) and representative clones from 14 day puromycin/G418 selected pCas9-
gRNA(nluc) + pMN::nluc(stop) + 125 bp oligo parasites in Fig. 4C. Lower: representative DNA sequencing trace 
(Genewiz sequencing and FinchTV sequence viewer) of PCR products amplifying the nanoluciferase gene from 
T. vaginalis genomic DNA preparations. Highlighted (and arrows) are residues G50C and A54T which are the 
site of the two predicted modifications for repair of the stop codon (A54T) and oligo-modification confirmatory 
mutation (G50C). Immunoblot analyses in Fig. 4C and D were imaged using a Bio-Rad Gel Doc and ImageLab 
software. Full length blots/gels are presented in Supplementary Figure S5.
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Figure 5. CRISPR-directed KO of ferredoxin-1 and mif. (A) Cartoon representation of the KO scheme using 
nucleofection of parasites with a linearized neo resistance gene flanked by the ferredoxin-1 UTRs and a plasmid 
containing Cas9 and Fd gRNA (pCas9-gRNA(Fd)) followed by selection for G418-resistance (image not to 
scale). The resulting parasites were then screened for the presence of the KO and wt alleles using sequence-
specific primers (horizontal arrows). (B) PCR analysis of G418-resistant clones for the presence of the neo 
resistance gene in the ferredoxin-1 locus. PCR screens utilized primers specific to the neo resistance gene 
(yellow arrows in 5 A) combined with primers specific to the ferredoxin-1 locus (blue arrows in 5 A) in regions 
outside the region present in the original KO PCR introduced by nucleofection. The 5′ end PCR screen (upper 
panel) predicts a product of 1665 bp and the 3′ PCR screen (middle panel) predicts a product of 1236 bp if the 
neo gene is present in the ferredoxin-1 locus. Lowest panel: PCR analysis of the ferredoxin-1 gene in clones. 
Amplification utilized primers specific to the wild-type ferredoxin-1 (yielding a 324 bp product, if present). The 
PCR products for the different panels were run in parallel from reactions on 100 ng of the indicated genomic 
DNA extracts and resolved on separate agarose gels then imaged using a Bio-Rad Gel Doc and ImageLab 
software. (C) Immunoblot protein analysis of the clones yielding positive PCR products for KO in Fig. 5B. Total 
protein extracts were resolved by SDS-PAGE and immunoblotted using anti-Ferredoxin-1 and TvGAPDH 
antibodies. All immunoblots contained equal amounts of the same experimental samples and were analyzed 
in parallel using a Bio-Rad Gel Doc and ImageLab software. (D) Cartoon representation of the KO scheme 
using nucleofection of parasites with a linearized neo resistance (NeoR) gene flanked by the mif UTRs and a 
plasmid containing Cas9 and mif gRNAs (pCas9-gRNA(mif)), followed by selection for G418- and puromycin-
resistance (image not to scale). The resulting parasites were then screened for the presence of the KO and wt 
alleles using sequence-specific primers (horizontal arrows). (E) PCR analysis of G418 and puromycin-resistant 
clones for the presence of the neo resistance gene in the mif locus. PCR screens utilized primers specific to the 
neo resistance gene (yellow arrows in 5D) combined with primers specific to the mif locus (orange arrows in 
5D) in regions outside the region present in the original KO PCR introduced by nucleofection. The 5′ end PCR 
screen (upper panel) predicts a product of 1290 bp and the 3′ PCR screen (middle panel) predicts a product 
of 1220 bp if the neo gene is present in the mif locus. Lowest panel: PCR analysis of the mif gene in clones. 
Amplification utilized primers specific to the wild-type mif gene (yielding a 500 bp product, if present). The PCR 
products for the different panels were run in parallel from reactions on 100 ng of the indicated genomic DNA 
extracts and resolved on separate agarose gels then imaged using a Bio-Rad Gel Doc and ImageLab software. 
(F) Immunoblot protein analysis of the clones yielding positive PCR products for KO in Fig. 5E. Total protein 
extracts were resolved by SDS-PAGE and immunoblotted using anti-MIF and TvGAPDH antibodies. All 
immunoblots contained equal amounts of the same experimental samples and were analyzed in parallel using a 
Bio-Rad Gel Doc and ImageLab software. Full length blots/gels are presented in Supplementary Figure S5.
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To further test the CRISPR/Cas9 system, we attempted to knockout the single copy mif gene, which codes for a 
homologue of the human macrophage migration inhibitory factor (MIF) and was recently reported to affect host 
cell physiology68. A neomycin resistance (NeoR) gene flanked by ~1000 bp of the 5′ and 3′ UTRs of mif was con-
structed (Fig. 5D). To illustrate the ability to use CRISPR/Cas9 in multiple T. vaginalis strains, the B7RC2 strain22 
was used. Parasites were co-nucleofected with the pCas9-gRNA(mif) plasmid expressing a gRNA targeting the 
5′ end of the gene and an ~2800 bp PCR product containing the NeoR gene flanked by mif gene 5′ and 3′ UTRs 
(Fig. 5D). After selection for parasites resistant to G418 and puromycin, parasites were screened for the presence 
of the NeoR gene in the mif locus, using PCR and primers that sit just outside the mif UTRs included in the 
~2800 bp PCR product. Positive amplicons of expected size were observed in the pCas9-gRNA(mif) nucleofected 
parasites (Fig. 5E). Control reactions wherein parasites were nucleofected with only the linear KO PCR prod-
uct survived G418 selection, however no positive PCR signal was observed for the NeoR gene in the mif locus 
(Supplementary Figure S4). We further examined these control parasites lacking the pCas9-gRNA(mif) plasmid 
by screening 800 cells, split into 40 subpopulations of 20 parasites each to directly test whether the NeoR gene 
was in the mif locus. No PCR product was detected in any of the 40 subpopulations (Supplementary Figure S4). 
This is in contrast with obtaining positive PCR signal for NeoR integration at the mif locus in 39/40 subpopula-
tions of the parasites nucleofected with both the pCas9-gRNA(mif) plasmid and the linear KO PCR product. To 
confirm that the mif gene was knocked out in these NeoR PCR positive populations, parasites were cloned using 
limited-dilution cloning. Two clones (“Δmif clone 1” and “Δmif clone 2”) were randomly selected and tested for 
the presence of the NeoR gene in the mif locus and the absence of the wild-type mif gene (Fig. 5E). Confirmation 
of the sequence of all PCR products clearly demonstrated that both clones contain the NeoR gene in the mif 
locus and also lack the endogenous mif gene (Fig. 5E). Immunoblot analysis using an antibody that detects MIF 
likewise confirmed the loss of the MIF protein in both clones (Fig. 5F). Together, our findings demonstrate that 
CRISPR/Cas9 can be used to disrupt gene sequences in the T. vaginalis genome by a homology-directed repair 
pathway.
Discussion
Here we describe the development of a system to achieve CRISPR/Cas9 gene modification and gene knockout 
in Trichomonas vaginalis. Three technical advances made this possible. One was to decrease the toxicity of Cas9 
when expressed in T. vaginalis by using FKBP-DD/Shield-1 regulated expression of the endonuclease. The second 
was to increase transfection efficiency using nucleofection. These together, with the use of a sensitive nanolu-
ciferase reporter assay to detect homology directed repair of a premature stop codon back to wild-type firstly 
described by Streipen and colleagues47,69, provided a sensitive assay to facilitate identifying optimal nucleofection 
parameters. Finally, we were able to utilize the strong RNA polymerase III T. vaginalis U6 promoter to drive 
transcription of a sequence-customizable gRNA. This, the first report of CRISPR/Cas9 gene modification in T. 
vaginalis, will greatly enhance the ability to test gene function in this pathogen.
It has been previously reported that expression of Cas9 in various organisms leads to cell growth issues43. 
We found that initial attempts at plasmid-based Cas9 expression by transfection and selection of T. vaginalis 
repeatedly failed. Different reports have addressed decreased cell growth by transient transfection of cas9-gRNA 
from plasmids or transfecting with Cas9 mRNA or holoenzymes70–72. We chose to regulate Cas9 expression at the 
protein through fusion to the FKBP-destabilization domain (FKBP-DD), which by default sends proteins for pro-
teolytic degradation. In the presence of a stabilizing ligand Shield-1, the protein accumulates54,55. We found that 
this method allowed the regulation of cellular Cas9 levels in T. vaginalis, which in turn yielded viable parasites 
expressing sufficient, but not toxic, levels of Cas9.
Testing the biological role of genes in T. vaginalis has previously been severely compromised by limited tech-
nologies to alter the highly, repetitive genome of this parasite52. Only two previous reports have successfully 
knocked out T. vaginalis genes28,29 and knockdown of gene expression is limited to four reports30–33. Lacking the 
ability to knockout gene expression, researchers have primarily relied on episomal over-expression of gene vari-
ants to study protein function.
One reason that homologous gene replacement has been hampered in T. vaginalis is the poor transfection 
efficiency achieved with standard electroporation. Here, using nucleofection64,73, we have greatly enhanced the 
transfection efficiency by 20-fold or greater as compared to that achieved using electroporation method. This 
enhancement of transfection efficiency has enhanced both the probability of successful modification of genes and 
the ability to detect the modifications by sensitive techniques such as nanoluciferase activity assays or PCR. Thus, 
developing successful nucleofection methods allowing sensitive screening and selection for gene modifications 
was key to our ability to achieve and monitor CRISPR/Cas9 modification of T. vaginalis genes.
Our analyses of the T. vaginalis genome for homologs of NHEJ pathway components indicated that 
this pathway is absent or highly divergent from other organisms. Based on this observation, we focused on 
homology-directed repair pathways to establish the use of CRISPR/Cas9 in this parasite. We were able to detect 
CRISPR activity using the sensitive technique of early termination mutation repair first used to demonstrate 
CRISPR in Crytosporidium parvum47. Using a 125 bp repair template of annealed oligonucleotides with flanks 
on both sides of the CRISPR cut site, we were able to repair an early termination codon restoring nanolucif-
erase activity as demonstrated by enzyme activity assays, immunoblot analysis and DNA sequencing. The repair 
template makes two specific point mutations both changing the stop codon to a tyrosine and a proximal gly-
cine to alanine. The nanoluciferase repair assay demonstrates that small oligonucleotides are sufficient to modify 
multi-target episomally maintained genes and thus the length of a homology template may not have to be large. 
Repair is due to homology-directed repair (HDR) using the oligonucleotide template, as opposed to NHEJ activ-
ity. Notably, in the absence of the HDR template, we did not observe signal of repaired nanoluciferase above 
background signal, consistent with the lack of NHEJ-mediated repair.
www.nature.com/scientificreports/
1 0SCIeNtIfIC RepoRts |  (2018) 8:270  | DOI:10.1038/s41598-017-18442-3
Nucleofection of pre-selected pMN::nluc(stop) parasites with pCas9-gRNA(nluc) and repair oligos resulted 
in an increase of nanoluciferase activity. This varied based on concentration of oligos with 100 μg working more 
effectively than 10 μg. Transient co-nucleofection of all DNA components (pMN::nluc(stop), pCas9-gRNA(nluc) 
and repair oligos) resulted in lower nanoluciferase signals, however, this could be overcome using drug selec-
tion to enrich for parasite populations containing DNAs required for CRISPR/Cas9-mediated repair. Using 
drug selection and cell cloning by limited dilution, we found that 91% of the clones had nanoluciferase activity 
above background. DNA sequencing of the clones confirmed the modification of the nluc(stop) to nluc(repaired), 
demonstrating CRISPR-Cas9 mediated repair of the nluc(stop) gene.
We have also demonstrated the ability to use CRISPR-Cas9 mediated homology-repair to eliminate two genes 
(ferredoxin-1 and mif) from the genome of T. vaginalis. CRISPR-mediated gene knock-out was achieved in two 
different T. vaginalis strains. The methods we have developed to increase transfection efficiency for both plasmids 
and KO cassettes and to direct CRISPR/Cas9 gene modification will greatly increase the success rate of gene 
knockouts in this parasite. The expanded toolkit for molecular modification of the T. vaginalis genome will signif-
icantly enhance the ability to assess gene function in this medically-important pathogen.
Methods
Parasite culture. Parasites (T. vaginalis strain B7RC222 and MSA 110374) were maintained by daily passage in 
modified TYM media75 supplemented with 10% heat-inactivated horse serum (Sigma), 10 U/ml penicillin/10 μg/
ml streptomycin (Invitrogen), 180 μM ferrous ammonium sulfate and 28 μM sulfosalicylic acid (completed TYM 
media). To select for the pMasterPAC (pMPAC)53,76 or pMasterNEO (pMN)22 plasmids, puromycin (AG scien-
tific) or G418 (Invitrogen) was added to cultures to a final concentration of 30 μg/ml and 100 μg/ml, respectively.
Plasmid constructs. Plasmid pMN::cas9 was created by PCR amplification of the human codon opti-
mized cas9 gene of plasmid pMJ92056 using primers For-hcas9-SacII and Rev-hcas9-Bam. All oligos used 
in this study are listed in Supplemental Table 1. The resulting hcas9 product was digested with SacII/BamHI 
and ligated to pMN::fkbp. The resulting construct was then PCR amplified using primers For-dS-HuCas9 and 
Rev-MN3UTR to silently mutate an internal SacI sequence. This product was then used in megaprimer PCR with 
primer For-MN-SacXho and subsequently digested with SacI/BamHI and ligated into pMN::fkbp to produce 
pMN::fkbp-cas9. To create the pMPAC::fkbp-cas9 construct, pMN::fkbp-cas9 was digested with SacI/BamHI and 
the product cloned into the pMPAC-empty vector plasmid (pMPAC::EV). The gRNA cassette was constructed 
by PCR amplification of a synthetic gene construct (Table S1) containing the U6 seed region and gRNA scaf-
fold flanked upstream by the 360 bp 5′ of the U6 start nucleotide and downstream with 37 bp of the 3′ UTR of 
the U6 gene using primer U6_SacI_F1 and downstream 3′ UTR with primer U6_SacI_R1. The resulting prod-
uct was then digested with SacI and ligated to the unique SacI site in pMasterNEO53. The nluc gRNA was con-
structed by megaprimer amplification of the gRNA scaffold using primers For-Nluc-gRNA and U6_SacI_R1 
and then used in a megaprimer PCR with U6_SacI_F1. The resulting PCR product was digested with SacI and 
ligated to pMPAC::fkbp-cas9. The final construct was termed to pMPAC::fkbp-cas9-gRNA(nluc), abbreviated as 
pCas9-gRNA(nluc).
Construction of nanoluciferase plasmids utilized codon-optimized plasmid templates of nluc (wt) and nluc 
(Y18ochre, “dead”/stop) from the Nluc-Neo and Dead Nluc-Neo plasmids (a generous gift from the Boris 
Striepen laboratory, University of Georgia)47, respectively. For each nluc variant, a megaprimer PCR was per-
formed utilizing primers For-MN-SacXho and Rev-Nluc-Nde to amplify the 5′ UTR of a-SCS on pMasterNEO 
with a portion of the 5′ end of the nluc gene. The resulting products were gel-purified and used with primer 
Rev-Nluc-Kpn to amplify the remainder of nluc and nluc(stop). The PCR products were then digested with SacI/
KpnI and ligated to pMasterNEO such that the nluc (or repaired) sequence would by fused to a 2xHA epitope tag 
when translated. These plasmids were termed pMN::nluc and pMN::nluc(stop).
For construction of the pCas9-gRNA construct targeting the ferredoxin-1 gene (TVAG_003900), the 20 nt 
seed region of pMPAC::fkbp-cas9-gRNA(nluc) was replaced after the adenosine reside start with 19 nucleotides 
of the ferredoxin-1 gene (residues 5–23, 5′ - TCT CTC AAG TTT GCC GCT T) which lie 5′ upstream of a TGG 
PAM sequence. This was constructed by PCR amplification with primers For-gRNA-Fer-1 and U6_SacI_R1. The 
resulting PCR product was purified and used in a second PCR with primer U6_SacI_F1, followed by digestion 
with SacI and cloning into pMPAC::fkbp-cas9-gRNA(nluc). The resulting plasmid was termed pCas9-gRNA(Fd). 
For construction of the pCas9-gRNA construct targeting the mif gene (TVAG_219770), a dual gRNA was con-
structed. For each of the gRNAs the 20 nt seed region of pMPAC::fkbp-cas9-gRNA(nluc) was replaced after the 
adenosine reside start with 19 nucleotides of the mif gene. The mif sequences “g300” (5′ - CAA AGA GTG CTG 
AGG ACT G) and “g301” (5′ -CCA AAG AGTGCT GAG GAC T) were used to construct 19 nucleotides after the 
A in the seed region. Briefly, “g300” gRNA was constructed using PCR primers For-gRNA-g300 + U6-KpnI-R. 
The resulting product was purified and used in a second PCR with primer U6_SacI_F1. For “g301” gRNA was 
constructed using PCR primers For-gRNA-g301 + U6_SacI_R1. The resulting product was purified and used in 
a second PCR with primer U6-Kpn-F. Both PCR products were digested with KpnI, ligated together and gel puri-
fied. The resulting ligated product was then digested with SacI and ligated into pMPAC::fkbp-cas9-gRNA(nluc) 
producing the plasmid pMPAC::fkbp-cas9-gRNA(mif).
Construction of the ferredoxin KO cassette utilized 1000 bp upstream of the ferredoxin-1 start codon 
and 1000 bp downstream of the stop codon. Briefly, the neo resistance gene was PCR amplified using primer 
For-Neo-Eco and Rev-Neo-Bam. The resulting product was cloned into pSC-A (Stratagene) to produce the 
plasmid pSC-A::neo. PCR amplification of the 5′ UTR of ferredoxin utilized For-Fer-Kpn and Rev-Fer-Eco. The 
product was then digested with KpnI and EcoRI and cloned into the pSC-A::neo plasmid resulting in plasmid 
pSC-A::5′UTR-Fd-neo. Amplification of the 3′ UTR of ferredoxin utilized For-Fer-Bam and Rev-Fer-Sac. The 
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resulting product was digested with BamHI and SacI and cloned into the pSC-A::5′UTR-Fd-neo plasmid to pro-
duce plasmid pSC-A::5′UTR-Fd-neo-3′UTR-Fd (termed pKO-Fd).
Construction of the mif KO cassette utilized the same method used to generate the ferredoxin KO cassette 
except using mif gene-specific primers. Briefly, the 1000 bp upstream of the mif start codon and downstream 
of the stop codon were ligated to the NeoR gene. PCR amplification of the 1000 bp 5′ UTR upstream of the mif 
start codon utilized primers For-MIF-Kpn and Rev-MIF-Xho. The resulting product was digested with KpnI and 
XhoI and ligated to the pSC-A::neo plasmid resulting in plasmid pSC-A:: 5′UTR-mif-neo. PCR amplification of 
the 1000 bp 3′ UTR downstream of the mif stop codon utilized primers For-MIF-Bam and Rev-MIF-Sac. The 
resulting products were digested with BamHI and SacI and ligated to pSC-A::5′UTR-mif-neo to produce plasmid 
pSC-A::5′UTR-mif-neo-3′UTR-mif (termed pKO-mif).
Repair oligos/PCR. Repair oligos were constructed to target mutations in the nluc(stop) gene (Operon). 
Annealing of the 125 nt repair oligos utilized Repair-oligo-F and Repair-oligo-R. Annealing of the 50 nt repair 
oligos utilized Repair-oligo-F50 and Repair oligo-R50. An equal concentration of each repair oligo (200 μg) was 
annealed in 1x NEB T4 ligase buffer to create a stock of anneal oligos. For PCR amplification of the 125 bp repair 
sequence, primers For-125bp and Rev-125bp were used on the annealed 125 bp oligos above. For full length PCR 
of nluc, the digested (SacI/KpnI) and gel purified template of pMN::nluc was used as a PCR template using prim-
ers For-pMN-5UTR and Rev-Nluc-Kpn. The resulting product was treated with DpnI and then gel purified and 
amplified using the same primers. The final PCR product was precipitated, resuspended and quantified.
PCR amplification of the ferredoxin-1::neo knockout utilized the primers For-Fer-Kpn and Rev-Fer-Sac on a 
gel-purified product from a KpnI and SacI digestion of pKO-Fd. PCR amplification of the mif::neo knockout uti-
lized the same method described above with mif-specific primers For-MIF-Kpn and Rev-MIF-Sac. The resulting 
PCR products were treated with DpnI and confirmed to be free of template plasmid. The final KO PCR product 
was precipitated, resuspended and quantified.
Protein and Immunoblot analysis. For Shield-1 (Clontech) titration, parasites were seeded at 
1 × 105 cells/ml and treated with the indicated concentrations for 24 hours. For all immunoblot analyses, total 
protein was extracted and analyzed by SDS-PAGE using equal amount of soluble protein (10 μg). Protein was 
then transferred to a membrane which was subsequently incubated with an anti-Cas9 antibody (Clontech). For 
TvGAPDH detection, the membrane was incubated with an anti-TvGAPDH antibody (Cocalico Biologicals). 
Images were captured and analyzed by Bio Rad Gel Doc and ImageLab software (v. 5.1, Bio Rad). Resulting 
values were normalized to TvGAPDH signal and presented as the average +/− the standard deviation from two 
independent analyses. For detection of nanoluciferase-2xHA protein, total protein was extracted from parasites, 
resolved by SDS-PAGE, transferred to a PVDF membrane and incubated with an anti-HA antibody (Covance). 
For immunoblot analysis of the Ferredoxin-1 and MIF KO samples, total soluble protein from parasite samples 
was resolved by SDS-PAGE, transferred to a membrane and incubated with an anti-Ferredoxin-167, anti-MIF68 
and anti-TvGAPDH (Cocalico Biologicals) antibodies. Uncropped images for the corresponding immunoblots 
are included in Figure S5.
Nanoluciferase activity assay. A total of 1 × 106 parasites were harvested per reaction (in duplicate), 
washed in ice-cold 1x PBS with 5% sucrose (w/v) and resuspended at a concentration of 1 × 106 cells/100 μl in the 
same PBS/sucrose solution. Each 100 μl aliquot was mixed with 100 μl of completed NanoGlo luciferase assay 
reagent (Promega) and transferred to round bottomed white walled 96-well plates (Costar). Luciferase activity 
was analyzed by measurement with a Victor 3 model 1420 plate reader at 460 nm. Relative luminescence signal 
was measured in duplicate or triplicate for each assay and the average signal calculated +/− standard deviation.
Transfection of T. vaginalis using nucleofection and electroporation. Parasites were collected 
by centrifugation and resuspended in 100 μl T-cell, Parasite-1 or Parasite-2 buffers (Lonza) and the indicated 
amounts of DNA and parasites (1 × 107 or 5 × 107). Typically, 10 μg plasmid(s) and/or 100 μg of anneal oligos 
or PCR product was added. After five minutes of incubation at room temperature, parasites were nucleofected 
using an Amaxa nucleofector using the programs U-033, D-023 or X-100. For parasite electroporation, 5 × 107 
parasites were resuspended in 100 μl of completed TYM media and placed into electrocuvettes with the indicated 
DNA. Parasites were then electroporated using a single pulse of 350 V with 975 μF capacitance using a Bio Rad 
Gene Pulser II53. For both nucleofection and electroporation parasites were immediately resuspended into 50 ml 
of fresh completed TYM media. During recovery, parasites were treated with 1 μM Shield-1 where indicated.
Knockout of the ferredoxin-1 gene (TVAG_003900) in the MSA 1103 T. vaginalis strain74 utilized the 
nucleofection conditions (U-033 and T-cell buffer) with the substitution of pCas9-gRNA(Fd) or pMPAC::EV and 
50 μg of KO PCR product in duplicate. Parasites were recovered in completed TYM media for four hours and then 
selected for resistance to 50 μg/ml of G418. After an additional 16 hours, the parasites were harvested and resus-
pended in fresh completed TYM media and 100 μg/ml G418. After outgrowth from selection to 1 × 106 parasites/
ml, genomic DNA was extracted from ~1.5 × 107 parasites samples and PCR screening was done for the presence 
of the KO allele at the ferredoxin-1 locus (see below). The cultures with signal positive for ferredoxin-1 disruption 
were diluted and re-screened using limiting dilution until clones were obtained. The clones were screened for the 
presence of the neo gene at the ferredoxin locus as well as for the presence of the wild type ferredoxin-1 gene. All 
PCRs were performed on 100 ng of purified genomic DNA and utilized NEB Phusion polymerase, per the man-
ufacturers’ instructions. Screening for the wild-type gene used primers For-003900-1 and Rev-003900-1 (PCR 
cycle: 95 °C- 30 sec, 60 °C- 30 sec, 72 °C- 90 sec). Screening for the 5′ end of the ferredoxin-1::neo KO locus used 
primers For-003900-5UTR-1 and Rev-Neo-Int3 (PCR cycle: 95 °C- 30 sec, 60 °C- 30 sec, 72 °C- 90 sec). Screening 
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for the 3′ end of the ferredoxin-1::neo KO locus used primers For-Neo-Int2 and Rev-003900-3UTR-2 (PCR cycle: 
95 °C- 30 sec, 64 °C- 30 sec, 72 °C- 90 sec). All PCR products were confirmed by DNA sequencing.
Knockout of the mif gene (TVAG_219770) in T. vaginalis strain B7RC222 utilized nucleofection conditions 
described for the knockout of ferredoxin-1 above, except the D-023 program and V-kit buffer were utilizied, and 
pCas9-gRNA(mif) or water (for the negative control) and 100 μg of KO PCR product was used. B7RC2 parasites 
were recovered in completed TYM media for 24 hours and selected for resistance to 100 μg/ml of G418, and 30 
μg/ml of puromycin for the parasites that received pCas9-gRNA(mif). Negative control parasites that did not 
receive pCas9-gRNA(mif) were only selected with 100 μg/ml of G418. After an additional 24 hours, the parasites 
that received pCas9-gRNA(mif) were re-dosed with the 100 μg/ml G418, and 30 μg/ml of puromycin and con-
trol parasites were re-dosed with just 100 μg/ml G418. Drug selected parasites were then sub-populated into 20 
cells per well in a 96-well plate. When the parasites reached ~1 × 107 parasites/ml, genomic DNA was prepared 
for PCR screening. Initial screening was done utilizing the 5′ end of the mif::neo KO with primers For-219770-
5UTR-1 and Rev-Neo-Int4 (PCR cycle: 95 °C- 30 sec, 55 °C- 30 sec, 72 °C- 90 sec). A subpopulation with the cor-
rect Neo replacement based on 5′ UTR PCR analyses was cloned and then screened for the presence of the NeoR 
gene in the mif locus using both the 5′ primer described above and the 3′ primer For-Neo-Int3 and Rev-219770-
3UTR-1 (PCR cycle: 95 °C- 30 sec, 55 °C- 30 sec, 72 °C- 90 sec). Screening for the wild-type mif gene used primers 
For-219770-1 and Rev-219770-1 (PCR cycle: 95 °C- 30 sec, 55 °C- 30 sec, 72 °C- 30 sec). All PCR products were 
confirmed by DNA sequencing.
RT-PCR analysis of gRNA expression. Total RNA was isolated from ~1.5 × 107 parasites using the 
Direct-zol RNA Miniprep kit (Zymo) and then fractionated into small RNAs using the RNA Clean and 
Concentrator kit (Zymo). Small RNAs were further treated with the TURBO DNA-free kit (Ambion). Poly-A tails 
were then added using the Poly(A) polymerase tailing Kit (Ambion). Small RNAs were quantified and cDNA 
created by utilizing an equivalent amount of RNA in the Superscript III first strand synthesis system for RT-PCR 
(Invitrogen) using the provided oligo-dT20 primer. All PCRs were performed on one microliter of the result-
ing cDNA and utilized NEB Phusion polymerase, per the manufacturers’ instructions. For the gRNA, primers 
For-gRNA and Rev-gRNA were used to detect the gRNA and primers For-U6 and Rev-U6 were used to detect 
the U6 snRNA (for both, the PCR cycle: 98 °C- 10 sec, 55 °C- 20 sec, 72 °C- 8 sec). All samples were resolved on 
agarose-TBE gels, stained with ethidium bromide and imaged by Bio-Rad Gel Doc, as above.
Data Availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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